



SPLUNC1 is a novel marker of disease severity and airway infection in bronchiectasis

Holly R. Keir¹, Amelia Shoemark ^{1,2}, Jeffrey T.J. Huang³ and James D. Chalmers¹

¹Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK. ²Royal Brompton Hospital, Primary Ciliary Dyskinesia Centre, Paediatric Respiratory Medicine, London, UK. ³TMRC Laboratory, University of Dundee, Dundee, UK.

Corresponding author: James D. Chalmers (jchalmers@dundee.ac.uk)



Shareable abstract (@ERSpublications)

Having been shown to be a biomarker of severity in cystic fibrosis, this study shows SPLUNC1 is also a novel marker of severity and lung infections in non-CF bronchiectasis <https://bit.ly/3ABzEdc>

Cite this article as: Keir HR, Shoemark A, Huang JTJ, *et al.* SPLUNC1 is a novel marker of disease severity and airway infection in bronchiectasis. *Eur Respir J* 2021; 58: 2101840 [DOI: 10.1183/13993003.01840-2021].

This single-page version can be shared freely online.

Copyright ©The authors 2021.
For reproduction rights and
permissions contact
permissions@ersnet.org

Received: 30 June 2021
Accepted: 5 Aug 2021

To the Editor:

Biomarkers of disease severity are urgently needed to guide precision medicine in airway diseases [1, 2].